Abstract | G protein-coupled receptors (GPCRs) mediate physiological responses to various ligands, such as hormones, neurotransmitters and sensory stimuli. The signalling and trafficking properties of GPCRs are often highly malleable depending on the cellular context. Such fine-tuning of GPCR function can be attributed in many cases to receptor-interacting proteins that are differentially expressed in distinct cell types. In some cases these GPCR-interacting partners directly mediate receptor signalling, whereas in other cases they act mainly as scaffolds to modulate G protein-mediated signalling. Furthermore, GPCR-interacting proteins can have a big impact on the regulation of GPCR trafficking, localization and/or pharmacological properties. 
1
. The approximately 1,000 members of the GPCR family exhibit a conserved 7-transmembrane domain topology and can be divided into 3 main subfamilies, termed A, B and C, based on sequence similarity. The canonical view of how GPCRs regulate cellular physiology is that the binding of ligands (such as hormones, neurotransmitters or sensory stimuli) induces conformational changes in the transmembrane and intracellular domains of the receptor, thereby allowing interactions with heterotrimeric G proteins. Activated GPCRs act as guanine nucleotide exchange factors (GEFs) for the α subunits of heterotrimeric G proteins, catalysing the release of GDP and the binding of GTP for G protein activation. The activated G protein subunits (α•GTP and βγ) can then associate with downstream effectors to modulate various aspects of cellular physiology.
In addition to interacting with G proteins, agonistbound GPCRs associate with GPCR kinases (GRKs), leading to receptor phosphorylation. GRKs are a family of seven related kinases (GRK1-GRK7) that have differential patterns of distribution across tissues and distinct preferences for binding to certain receptors [2] [3] [4] . However, a common outcome of GPCR phosphorylation by GRKs is a decrease in GPCR interactions with G proteins and an increase in GPCR interactions with arrestins (members of a family of four closely related scaffold proteins). The interaction of GPCRs with arrestins further inhibits GPCR signalling through G proteins and simultaneously turns on other signalling pathways that are initiated by the arrestin-mediated recruitment of signalling proteins to activated GPCRs 2 . Furthermore, arrestins can directly link active receptors to clathrin-coated pits to facilitate receptor endocytosis, which is an important process controlling the desensitization and resensitization of GPCR activity 5 .
Interactions with G proteins, GRKs and arrestins have been intensively studied for numerous GPCRs and have been exhaustively reviewed elsewhere [2] [3] [4] [5] . For this reason, these broadly important interactions, which now represent a canonical model of GPCR regulation
, are not further reviewed here. Similarly, the importance of homomeric and heteromeric interactions between GPCRs has also been thoroughly reviewed elsewhere [6] [7] [8] and is not addressed here. The focus of this Review is on recent advances in the characterization of receptorselective GPCR associations with various proteins outside the four previously mentioned families of general GPCR-interacting proteins (G proteins, GRKs, arrestins and other receptors). These GPCR-selective partners can mediate GPCR signalling, organize GPCR signalling through G proteins, direct GPCR trafficking, anchor GPCRs in particular subcellular areas and/or influence GPCR pharmacology. As many of these partners exhibit limited patterns of tissue expression, these interactions can also help to explain cell type-specific fine-tuning of GPCR functional activity.
Mediation of GPCR signalling
For a GPCR-interacting protein to be considered a mediator of GPCR signalling, it would seem that the protein's interaction with the receptor needs to be regulated by agonist stimulation, as agonist-induced For example, GPCR interactions with G proteins, GRKs and arrestins are strongly enhanced by agonist stimulation [1] [2] [3] [4] [5] . In addition, other GPCR-interacting proteins interact with speci fic GPCRs in an agonist-promoted manner to mediate particular aspects of receptor signalling, and these examples are considered in this section. By contrast, some GPCR-interacting proteins associate with receptors in an agonist-independent manner. Such proteins can potentially modulate G protein-mediated signal ling, as described in the next section, but they should not be considered mediators of GPCR signalling as their interactions with GPCRs are not influenced by agonist stimulation. If a GPCR can be considered analogous in some ways to a gun, then ligand-dependent interactors that mediate signalling are analogous to bullets and ligand-independent interactors that modulate signalling are analogous to silencers and scopes, which influence gun function but do not directly mediate the effects of guns on targets.
Agonist-promoted interactors that mediate signalling. Several GPCRs have been shown to initiate cellular signalling through agonist-promoted interactions with members of the janus kinase (Jak) family of nonreceptor protein tyrosine kinases. For example, the
Box 1 | Canonical mechanisms of GPCR signalling
In the classical view of G protein-coupled receptor (GPCR) signalling, an agonist binds to extracellular and/or transmembrane regions of the receptor, leading to its interaction with heterotrimeric G proteins. The GPCR acts as a guanine nucleotide exchange factor, catalysing the exchange of GDP for GTP on the Gα subunit and inducing dissociation of the Gα and Gβγ subunits from each other and from the GPCR (see the figure, part a). Activated α•GTP subunits, of which there are multiple subtypes, including Gα s , Gα i , Gα 12/13 and Gα q , subsequently bind to and regulate the activity of effectors such as adenylyl cyclase, RhoGEF and phospholipase Cβ (PLCβ). These modulate downstream effectors directly or by generating second messengers (such as cyclic AMP, diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (Ins(1,4,5)P 3 ) that modulate further downstream effectors, such as protein kinase A (PKA) and protein kinase C (PKC). Following their liberation from the heterotrimeric G protein complex, the βγ subunits can also bind to and regulate certain downstream effectors, such as ion channels and PLCβ. G protein-mediated signalling by agonist-activated GPCRs can be terminated through GPCR phosphorylation by GPCR kinases (GRKs) and concomitant GPCR association with arrestins, which interact with clathrin and the clathrin adaptor AP2 to drive GPCR internalization into endosomes (see the figure, part b) [2] [3] [4] [5] . GPCR internalization regulates the functional process of receptor desensitization. Recruitment of arrestins to activated GPCRs can also lead to the initiation of distinct arrestin-mediated signalling pathways, including activation of the mitogen-activated protein kinase extracellular signal-regulated kinase (ERK) pathway. Following internalization after association with arrestins, GPCRs can be trafficked to lysosomes, where they are ultimately degraded, or to recycling endosomes for recycling back to the cell surface in the functional process of resensitization -whereby the cell is resensitized for another round of signalling. Interestingly, 'biased' agonists have been recently characterized that specifically activate G protein-mediated signalling pathways over arrestin-mediated GPCR signalling pathways, or vice versa 151, 152 . This new concept illustrates the importance of characterizing all GPCR downstream signalling pathways in order to fully exploit the therapeutic potential of clinically important receptors. Nature Reviews | Molecular Cell Biology agonist-dependent activation of type 1 angiotensin II receptor (AGTR1) can recruit a complex of JAK2 and tyrosine phosphatase non-receptor type 11 (PTPn11; also known as SHP2) to associate with the AGTR1 carboxyl terminus, which facilitates JAK2 phosphorylation and activation 9, 10 . Activated JAK2 can then recruit and phosphorylate members of the signal transducers and activators of transcription (STAT) family of transcription factors. Phosphorylated STAT dissociates from JAK2 and translocates to the nucleus to regulate the transcription of target genes (FIG. 1a) . The agonistpromoted interaction between JAK2 and AGTR1 shows an additional signalling avenue for AGTR1, beyond the receptor's well-established coupling to the G protein subunit Gα q . It can also help to explain certain effects of AGTR1 stimulation on cellular physiology that are not explained by G protein-mediated signalling 11 . Interestingly, AGTR1 coupling to Gα q can induce a rise in intracellular Ca 2+ that further potentiates Jak-STAT signalling by this GPCR 12, 13 , providing an example of how G protein-dependent and G protein-independent signalling mechanisms can in some cases work synergistically. Another GPCR that can interact with JAK2 is platelet-activating factor receptor (PTAFR), which associates with a tyrosine kinase 2 (TYK2)-JAK2 complex in an agonist-regulated manner 14, 15 GPCR interactions with proteins that possess PDZ domains can also, in some cases, mediate agonistpromoted GPCR signalling. PDZ domains, named after the first three proteins in which they were discovered (Postsynaptic density protein 95, Discs large and Zonula occludens protein 1), can mediate high-affinity interactions with specific motifs at the distal C termini of target proteins 16 . For example, the PDZ protein na + -H + exchange regulatory factor 1 (nHERF1; also known as EBP50 and SlC9A3R1) has been shown to associate in an agonist-promoted manner with the C terminus of the β 2 -adrenergic receptor (β 2 AR) 17, 18 . The recruitment of nHERF1 to β 2 AR disrupts the ability of nHERF1 to inhibit na + -H + exchanger type 3 (nHE3; also known as SlC9A3), providing a G protein-independent mechanism by which β 2 AR can activate na + -H + exchange in kidney cells 17 . The κ-type opioid receptor (κoPR) is another GPCR that can regulate na + -H + exchange through agonist-induced interactions with nHERF1 (ReFs 19, 20) . Interestingly, the studies on κoPR provide an example of how interactions between a GPCR and a protein such as nHERF1 can confer cell type-specific signalling to a given GPCR: κoPR stimulation robustly activates nHE3 activity in cell lines expressing high levels of nHERF1 but not in other cell lines that lack significant nHERF1 expression 20 .
Agonist-disrupted interactors that mediate signalling. In addition to the above examples of how agonist-promoted associations of GPCR-interacting proteins with GPCRs mediate aspects of GPCR signalling, the disruption of interactions between a GPCR and a cytoplasmic binding partner can also initiate cellular signalling. For example, it has been shown that agonist stimulation of somatostatin receptor type 2 (SSTR2) disrupts its constitutive association with the phosphoinositide 3-kinase (PI3K) subunit p85 to negatively regulate PI3K signalling 21 (FIG. 1b) . In the absence of agonist, association of p85 with the first intracellular loop of SSTR2 constitutively enhances PI3K activity to promote cell survival through the Akt pathway. However, following agonist stimulation of SSTR2, association of the receptor with p85 is disrupted, leading to decreased PI3K activity and sensitization of cells to stimu li that induce apoptosis 21 . Thus, even though the classical examples of proteins that mediate GPCR signalling (G proteins and arrestins) exhibit enhanced associations with receptors following agonist stimulation, it is evident that as long as a GPCR-interacting partner exhibits some type of change in its location and/or activity in response to agonist stimulation, this can be sufficient to initiate cellular signalling.
Modulation of GPCR signalling
Some GPCR-interacting partners increase the speed and efficiency of GPCR signalling by acting as scaffolds to tether downstream effectors in close proximity to the receptor. other GPCR-interacting partners can decrease the intensity and/or time course of GPCR signalling by disrupting the association of GPCRs with G proteins or, in some cases, by recruiting negative regulators of GPCR signalling. By finely tuning the spatial and Weaker G protein signalling
Second messenger
An intracellular signal, such as cAMP, diacylglycerol or inositol triphosphate, that is rapidly and transiently synthesized following receptor activation in order to further amplify the signal transduction cascade.
temporal resolution of signalling, certain GPCR interactors can dramatically affect the ability of GPCRs to transduce extracellular stimuli into changes in cellular physiology.
Interactors that enhance G protein-mediated signalling.
The visual system of Drosophila melanogaster has long been an important model system for studying fast and efficient G protein-mediated signalling. visual signalling in D. melanogaster is mediated by light stimu lation of the GPCR rhodopsin, which couples to Gα q to activate phospholipase Cβ (PlCβ). Active PlCβ leads to the generation of the second messengers inositol-1,4,5-trisphosphate (Ins(1,4,5)P 3 ) and diacylglycerol and to the opening of the Ca 2+ transient receptor potential channels (TRPCs). The influx of Ca 2+ and the production of diacylglycerol lead to activation of protein kinase C (PKC), which plays a key part in the termination of visual signalling. Interestingly, almost all of the components of the D. melanogaster visual signalling pathway are tethered together by a large PDZ domain-containing scaffold protein known as Inactivation-no-after-potential D protein (InAD), which associates with rhodopsin, TRPC, PlCβ and PKC [22] [23] [24] [25] [26] [27] [28] . By tethering these downstream effectors in close proximity to rhodopsin, InAD creates an efficient signalling complex that dramatically increases the speed and amplitude of physiological responses to light stimulation 29 .
Analogous to D. melanogaster InAD, some mammalian PDZ scaffold proteins have been found to interact with GPCRs to enhance the efficiency of GPCR-stimulated G protein signalling. For example, the association of nHERF1 and/or the closely related protein nHERF2 (also known as SlC9A3R2) with various GPCRs, including parathyroid hormone 1 receptor (PTH1R) [30] [31] [32] [33] [34] , lysophosphatidic acid receptor 2 (lPAR2) 35 , purinergic receptor (P2RY1) 36 and metabotropic glutamate receptor 5 (mGluR5) 37 , can enhance their PlCβ-mediated signalling. unlike the aforementioned interactions of nHERF1 with β 2 AR and κoPR, which are regulated by agonists, the associations of the nHERF proteins with PTH1R, lPAR2, P2RY1 and mGluR5 are not altered by agonist stimulation and they mainly seem to enhance G protein-mediated signalling. Interestingly, many known nHERF-binding partners (in addition to GPCRs and nHE3) are components of Gα q -PlCβ signalling pathways; for example, Gα q
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, several TRPCs 39, 40 , various isoforms of PlCβ 36, 41 , PKC 42 and protein kinase D (PKD) 43 . The interaction of nHERF2 with PTH1R provides a particularly compelling example as to how receptor-interacting scaffolds can help to explain cell type-specific fine-tuning of GPCR signalling. In osteoblast-like RoS 17/2.8 cells (which do not express detectable levels of nHERF proteins) PTH1R signals mainly by regulating adenylyl cyclase, but in human umbilical vein endo thelial ECv304 cells (which contain high levels of both nHERF1 and nHERF2) PTH1R signals mainly through PlCβ regulation 30 (FIG. 2a) . Thus, the enigmatic ability of PTH1R to signal by regulating adenylyl cyclase in some cell types but PlCβ in other cell types might be accounted for in many cases by differential cellular expression of the nHERF proteins 44 . In addition to nHERF proteins and InAD, various other PDZ scaffold proteins have been shown to associate with specific GPCRs to enhance certain signalling pathways (TABLe 1 49 . Thus, lPAR2 can preferentially couple to downstream PlCβ activation 35 , mAPK activation 48 or Rho activation 49 , in a cell type-specific manner, depending on which lPAR2-interacting PDZ scaffold protein is expressed. other prominent examples of GPCR-associated proteins that enhance the efficiency of G protein-mediated signalling are the Homer proteins, + exchange regulatory factor (NHERF) scaffold proteins and parathyroid hormone 1 receptor (PTH1R) leads to a preferential enhancement of downstream Gα q -mediated signalling by PTH1R. Through its various protein-protein interaction domains, NHERF not only binds to PTH1R but also tethers multiple downstream signalling effectors, such as phospholipase Cβ (PLCβ), protein kinase C (PKC) and transient receptor potential channel (TRPC), in close proximity to the PTH1R. This creates an efficient complex for preferential Gα q -mediated signalling. However, when PTH1R is in a cell type or cellular compartment in which NHERF proteins are absent, PTH1R preferentially signals through Gα s to activate adenylyl cyclase. b | By contrast, periplakin can associate with μ-type opioid receptor (μOPR) to impair G protein-mediated signalling by an unknown mechanism. However, in cell types or cellular compartments where periplakin is not found, μOPR ligands can more robustly activate the receptor to stimulate signalling by G proteins. GPCR, G protein-coupled receptor.
which associate with mGluR1 and mGluR5 (ReFs 50-53), and members of the A-kinase anchoring protein (AKAP) family, which interact with β-adrenergic receptors [54] [55] [56] [57] [58] . In addition, Homer proteins also interact with intracellular Ins(1,4,5)P 3 receptors, thereby linking Ins(1,4,5)P 3 receptors, mGluRs and other components to increase the efficiency of mGluR-stimulate d Ca 2+ signalling 52, 59, 60 .
The AKAPs were originally named because of their associations with protein kinase A (PKA). Indeed, the interactions of A-kinase anchor protein 79 kDa (AKAP79; also known as AKAP5) 55 and AKAP250 (also known as AKAP12 and gravin) 54, 56, 57 with β 2 AR tether PKA in the vicinity of the receptor and increase the efficiency of PKA-mediated phosphorylation of various substrates that are downstream of receptor activation, including β 2 AR itself. The consequences of the increased functional relationship between PKA and β 2 AR include the enhanced efficiency of receptor resensitization 54, 57 and more robust β 2 AR-mediated ERK signalling 55 .
Interactors that reduce G protein-mediated signalling. In contrast to the above examples of GPCR-interacting proteins, which increase the efficiency of certain GPCRstimulated signalling pathways, some GPCR-interacting proteins associate with GPCRs to decrease the efficiency of G protein-mediated signalling. The arrestins are perhaps the most general example of this phenomenon. A more receptor-specific example is spinophilin, which interacts with the third intracellular loop of a few GPCRs, including members of the dopamine, adrenergic and muscarinic acetylcholine receptor families [61] [62] [63] [64] [65] . Spinophilin also binds to several members of the regulators of G protein signalling (RGS) family of proteins. RGS proteins tightly regulate the intensity and time course of GPCR signalling by accelerating the inherent GTPase activity of activated Gα subunits. Thus, spinophilin tethers RGS proteins in close proximity to GPCRs to attenuate receptor-stimulate d G protein signalling 63, 64 . Interestingly, RGS proteins can also associate directly with the intracellular regions of some GPCRs to inhibit their signalling and exert cell type-specific regulation of their activity [66] [67] [68] [69] [70] [71] . RGS proteins have been reviewed in detail elsewhere 72, 73 and are therefore not discussed further here.
Calmodulin is another protein that can interact with a variety of GPCRs to modulate their functional properties. This widely expressed Ca 2+ -binding protein can associate in a Ca 2+ -sensitive manner with mGluRs [74] [75] [76] [77] and serotonin (also known as 5-hydroxytryptamine (5-HT)) [78] [79] [80] , dopamine 81, 82 and other [83] [84] [85] receptors. The functional effects of calmodulin interaction vary depending on the GPCR, but perhaps the most commonly reported effect of calmodulin-GPCR interaction is an attenuation of G protein coupling 79, 81, 83, 85 . As stimulation of many GPCRs can result in a downstream increase in cellular Ca 2+ levels, the Ca 2+ -dependent interaction of calmodulin with GPCRs can, in some cases, represent a form of feedback inhibition that restrains GPCR-initiated G protein signalling. However, G protein-independent signalling pathways can actually be potentiated by GPCR inter actions with calmodulin in some situations, as calmodulin association with the 5-HT2C receptor strongly promotes arrestin-mediated signalling (but not G protein-mediated signalling) by the receptor in both transfected cells and cultured neurons 80 . Two other proteins that can associate with a few GPCRs to tone down G protein-mediated signalling are periplakin and neurochondrin. Periplakin was first reported to associate with the C-terminus of μ-type opioid receptor (μoPR) 86 and melanin-concentrating hormone receptor 1 (mCHR1) 87 , and neurochondrin was found to interact with the same region of the mCHR1 C terminus as periplakin 88 . Both periplakin and neurochondrin have recently been shown to also interact with a few other GPCRs 89 . For all of the GPCRs that associate with periplakin and neurochondrin, the primary functional consequence is an attenuation of G protein-mediated signalling [86] [87] [88] [89] (FIG. 2b) . As periplakin and neurochondrin exhibit discrete patterns of distribution in the brain and other tissues 89 , it seems likely that they contribute to the cell-context-dependent sculpting of receptor signalling for the various GPCRs with which they interact. Considered together with the other GPCR partners discussed in this section, the emerging theme is that GPCR-interacting proteins can exert bidirectional effects on the efficiency of G protein-mediated signalling to impart cell type-specific fine-tuning of GPCR activity.
Regulation of GPCR trafficking
GPCRs are typically trafficked to the plasma membrane to achieve functional activity. Following agonist stimulation, most receptors are internalized into endosomes and then either targeted for lysosomal degradation or recycled back to the plasma membrane. A number of GPCR-interacting proteins have been shown to exert dramatic effects on both the biosynthetic trafficking and the post-endocytic sorting of particular GPCRs.
Interactors that regulate biosynthetic trafficking. GPCRs must be properly folded after translation and, in most cases, transported to the plasma membrane to achieve functional activity. A number of GPCR-interacting proteins can regulate the folding, biosynthetic trafficking and surface expression of receptors in a cell type-and receptorspecific manner. A classic example is the D. melano gaster neither inactivation nor afterpotential protein A (nInAA), which associates with the GPCR rhodopsin to enhance the receptor's folding and forward trafficking 90, 91 . Similarly, Ran-binding protein 2 is a vertebrate homologue of nInAA that associates with vertebrate opsins to enhance the biosynthetic trafficking of these GPCRs 92 . Another protein that regulates rhodopsin trafficking is the dynein light chain component T-complex testis-specific protein 1 homologue (TCTEX1; also known as DYnlT1), which directly associates with vertebrate rhodopsin to promote its trafficking to the cell surface 93, 94 . other vertebrate proteins that have been found to act as chaperones to enhance GPCR-specific surface expression include glandular epithelial cell protein 1 (GEC1; also known as GABARAPl1) 95, 96 , receptor of activated protein kinase C1 (RACK1; also known as GnB2l1) 97 , dopamine receptorinteracting protein of 78 kDa (DRIP78; also known as DnAJC14) 98, 99 , AT2 receptor binding protein of 50 kDa (ATBP50) 100 and ubiquitin-specific-processing protease 4 (uSP4) 101 , which are listed in TABLe 2. For each of these GPCR-interacting proteins, their expression level in a given cell type can strongly influence the level of functional receptor expression for the particular GPCRs with which they interact. olfactory receptors, the largest subfamily of GPCRs, have proved notoriously difficult to study in heterologous cells (that is, in cells other than olfactory sensory neurons, which naturally express olfactory GPCRs) because of their poor trafficking to the plasma membrane 102 . This trafficking deficiency suggests a key role for chaperone proteins in the cell type-specific control of anterograde olfactory receptor trafficking in olfactory sensory neurons. Indeed, Caenorhabditis elegans odorant response exchange regulatory factor 1; NINAA, neither inactivation nor afterpotential protein A; NT, amino terminus; ODR, odorant response abnormal protein; OPR, opioid receptor; OR, olfactory receptor; PAR1, proteinase-activated receptor 1; PICK1, protein interacting with C kinase; PSD95, postsynaptic density protein 95; RACK1, receptor of activated protein kinase C1; RanBP2, Ran-binding protein 2; RAMP, receptor activity-modifying protein; REEP, receptor expression-enhancing protein; RTP, receptor transporting protein; SNX1, sorting nexin 1; SSTR3, somatostatin receptor type 3; TCTEXI, T-complex testis-specific protein 1; T2R, taste receptor type 2; TM, transmembrane; TXA2R, thromboxane A2 receptor; USP4, ubiquitin-specific-processing protease 4; V2R, vasopressin V2 receptor. abnormal protein 4 (oDR-4) is expressed exclusively in chemosensory neurons, where it regulates the forward trafficking of chemosensory receptors such as the GPCR oDR-10 (ReF. 103) . In vertebrates, two unrelated families of transmembrane proteins have been shown to associate with olfactory receptors to enhance receptor trafficking to the plasma membrane: the receptor transporting proteins (RTPs) and the receptor expression-enhancing proteins (REEPs) 104, 105 . Certain RTP and REEP isoforms are expressed exclusively in the olfactory epithelium, where they exert a cell type-specific enhancement of olfactory receptor trafficking 104 . However, other RTP and REEP isoforms are more widely expressed and can interact with other GPCRs, including bitter taste receptor type 2 (ReF. 106) and opioid receptors 107 , to enhance the trafficking of these GPCRs to the plasma membrane.
Analogous to the RTPs and REEPs, two other types of single-transmembrane proteins have been shown to control the biosynthetic trafficking of particular GPCRs. vomeronasal type 2 receptors (v2Rs) had proved difficult to study in heterologous cells until the observation that they interact with m10 major histocompatibility complex (mHC) molecules, which associate with the mHC component β2-microglobulin to promote the surface expression of v2Rs in heterologous cells 108 . In a similar manner, melanocortin receptor 2 (mC2R)-accessory protein (mRAP) and mRAP2 can directly interact with mC2R and dramatically enhance the receptor's surface expression [109] [110] [111] [112] [113] . The physiological importance of mC2R-mRAP interactions in vivo has been well established by studies revealing that naturally occurring mRAP mutations cause defects in mC2R trafficking and function, resulting in an inherited disease known as familial glucocorticoid deficiency type 2 (ReF. 109) .
Interactors that influence post-endocytic trafficking. most GPCRs undergo significant endocytosis from the plasma membrane in response to agonist stimulation. In some cases the receptors are recycled back to the plasma membrane, but in other cases they are targeted to lysosomes for degradation 5 . GPCR internalization is heavily influenced by two of the canonical families of GPCR-interacting proteins, the GRKs and the arrestins [2] [3] [4] [5] . However, certain other GPCR-interacting proteins can also regulate Following agonist-induced receptor endocytosis, some G protein-coupled receptors (GPCRs) are targeted for proteolytic and/or lysosomal degradation, whereas other GPCRs rapidly recycle back to the plasma membrane. a | The interaction between GPCR-associated sorting protein 1 (GASP1) and δ-type opioid receptor (δOPR) promotes the endocytic targeting of agonist-internalized δOPRs to lysosomes, where the receptors are degraded. However, in a distinct cellular compartment (or distinct cell type) that lacks GASP1, as shown on the left, δOPRs are rapidly recycled back to the plasma membrane. b | By contrast, the interaction between the GPCR-interacting protein Na + -H + exchange regulatory factor 1 (NHERF1; also known as EBP50 and SLC9A3R1) and the β 2 -adrenergic receptor (β 2 AR) promotes the rapid recycling of receptors following agonist-promoted internalization. However, in a distinct cellular compartment (or distinct cell type) that lacks NHERF1, as shown on the left, β 2 ARs are preferentially targeted to lysosomes for degradation.
Postsynaptic density
A specialized postsynaptic compartment, highly enriched in various scaffold proteins and receptors, that is found at all asymmetric (usually glutamatergic) synapses in vertebrate central nervous systems.
Cortical pyramidal neuron
The predominant type of neuron in the neocortex. It is named after its triangular cell body.
Palmitoylation
Post-translational modification of a protein by the covalent attachment of a palmitate (a 16-carbon saturated fatty acid) to a cysteine residue through a thioester bond.
Dystrophin-associated glycoprotein complex
A series of protein subcomplexes, including complexes of the adaptor protein dystrophin, cytoskeletal proteins, the sarcoglycan complex and the α,β-dystroglycan complex, which together are required to link the cytoskeleton to the extracelluar matrix in muscle cells.
the endocytic trafficking of GPCRs in a more receptorselective manner. For example, the GPCR-associated sorting proteins (GASPs) comprise a family of ten proteins, and the founding member, GASP1, was originally identified in a yeast two-hybrid screen for proteins that interact with the C terminus of the δ-type opioid receptor (δoPR) 114 . Association of δoPR with GASP1 promotes receptor trafficking to lysosomes following agoniststimulated endocytosis 114 (FIG. 3a) , and GASP1 has a similar effect on a few other GPCRs, including D2 dopamine receptor 115 and cannabinoid receptor 1 (ReFs 116, 117) . most of the GASP family members are preferentially expressed in the central nervous system (CnS) 118 , suggesting that they might act in a cell type-specific manner to control the post-endocytic fate (recycling versus degradation) of certain CnS-enriched GPCRs.
In addition to the members of the GASP family, a few other GPCR-interacting proteins influence the postendocytic sorting of particular receptors. For example, sorting nexin 1 (SnX1) directly associates with proteinaseactivated receptor 1 (PAR1; also known as F2R) to promote PAR1 post-endocytic trafficking to lysosomes 119, 120 . SnX1 can also bind to the C termini of several other GPCRs 121 , but how this influences the trafficking of these receptors is still unknown. In contrast to the effects of GASPs and SnX1, which associate with GPCRs to decrease receptor recycling to the plasma membrane, GPCR interactions with nHERF1 have been found to promote receptor recycling following endocytosis 19, [122] [123] [124] . As mentioned earlier, nHERF1 interactions with β 2 AR and κoPR mediate certain aspects of GPCR signalling, and nHERF interactions with other GPCRs can modulate signalling by G proteins. Interestingly, mutant versions of β 2 AR that cannot associate with nHERF1 are targeted much more robustly than wild-type receptors to lysosomes after agonist stimulation 122 , revealing that their interaction with nHERF1 promotes receptor recycling (FIG. 3b) . The association of κoPR with nHERF1 also favours GPCR recycling over GPCR targeting to lysosomes 19 , and interaction of PTH1R with nHERF1 increases the plasma membrane retention of this receptor 125 . moreover, transplantation of the nHERF1 binding motif onto the C termini of GPCRs that do not normally interact with nHERF1, such as δoPR, dramatically enhances the efficiency of receptor recycling back to the plasma membrane following endocytosis 123, 124 . These findings provide an example of how certain GPCR-interacting proteins, such as nHERF1, can act as signalling intermediates, regulators of G protein signalling and regulators of receptor trafficking, analogous to the multiple roles of arrestins in the signalling and trafficking of many GPCRs 2 .
Control of GPCR targeting
In addition to the effects of many of the aforementioned GPCR-interacting proteins on GPCR signalling and trafficking, some of these interactions control GPCR anchoring to discrete regions of the plasma membrane. For example, Homer proteins not only enhance the efficiency of mGluR1-and mGluR5-mediated Ca 2+ signalling (as described above), they also facilitate the clustering and anchoring of mGluR1-and mGluR5 in postsynaptic dendritic spines [126] [127] [128] . Consequently, mGluR1 and mGluR5 can be selectively localized near the postsynaptic density, positioning them to respond to the glutamate that is released into the synaptic cleft. members of the Shank family of PDZ scaffold proteins interact with both Homer proteins and mGluRs to further strengthen the anchoring of mGluRs to postsynaptic regions [129] [130] [131] . The Shank family of scaffolding proteins also induce clustering of the latrotoxinbinding GPCR latrophilin 1 (lPHn1; also known as Cl1 and CIRl1) in heterologous cells and colocalize with latrophilin 1 at synapses in native brain tissue 132, 133 . A variety of PDZ scaffold proteins, in addition to the Shank family, have been shown to regulate GPCR-specific clustering and anchoring. For example, interaction of PSD95 (also known as DlG4) with 5-HT2A receptors induces the clustering of 5-HT2A receptors in heterologous cells 134 and facilitates the targeting of 5-HT2A receptors to postsynaptic dendritic compartments in cultured cortical pyramidal neurons 135 . PSD95 also associates with the C terminus of β 1 AR to facilitate the clustering of this receptor with other components of the postsynaptic density, such as nmDA (N-methyl-d-aspartate) receptors 136 . The anchoring of both 5-HT2A receptor and β 1 AR to the plasma membrane as a result of their association with PSD95, which is known to be palmitoylated and therefore tightly membrane associated 137 , greatly reduces their agonist-induced internalization 134, 136, 138 . By contrast, PSD95 association with 5-HT2C receptors facilitates agonist-dependent internalization, and another PDZ scaffold protein, mAGuK p55 subfamily member 3 (mPP3), associates with 5-HT2C receptors to prevent agonist-dependent internalization and to stabilize the receptors at the cell surface in primary cortical neurons 139 . Furthermore, interaction of the mGluR7a C terminus with the PDZ scaffold protein PICK1 (protein interacting with C kinase) results in the specific clustering of mGluR7a at presynaptic sites 140, 141 , interaction of the α 1D -adrenergic receptor with syntrophins enables linkage to the dystrophin-associated glycoprotein complex in smooth muscle cells 142, 143 , and the interaction of SSTR3 with muPP1 enables SSTR3 to be targeted to tight junctions in epithelial cells 144 . These examples show how certain GPCR-interacting partners can selectively target GPCRs to specialized cellular compartments to promote the receptors' physiological activities.
Regulation of ligand binding
The vast majority of GPCR-interacting proteins described above associate with intracellular regions of the GPCRs. Therefore, they have no direct effects on the pharmacological properties of the GPCRs, which are typically determined by their extracellular and/or transmembrane domains. However, a few GPCR-interacting proteins have been shown to exert striking effects on the agonist selectivity of the GPCRs with which they interact. The most intensively studied examples of GPCR-interacting partners that regulate receptor pharmacology are receptor activitymodifying protein 1 (RAmP1), RAmP2 and RAmP3 (ReF. 145) . The RAmP proteins were initially identified in experiments designed to search for the receptor that was activated by calcitonin gene-related peptide (CGRP). Surprisingly, it was found that expression of a functional CGRP receptor required co-expression of an orphan GPCR, known as the calcitonin receptor-like receptor (CAlCRl; also known as CRlR), with a receptorinteracting partner -the single-transmembrane protein RAmP1 (ReF. 146) . when CAlCRl was co-expressed with RAmP2, this was shown to result in the formation of receptors activated not by CGRP, but rather by a related peptide known as adrenomedullin 146 . Subsequent work has revealed that CAlCRl can also interact with RAmP3 to form a distinct subtype of adrenomedullin receptor 147, 148 . moreover, expression of a distinct receptor, calcitonin receptor (CAlCR), with any of the RAmPs results in the formation of receptors with unique pharmacological properties, including the preferential activation of some RAmP-CAlCR combinations by a distinct peptide known as amylin 149, 150 . It is clear from work in this area that the pharmacological properties of CAlCR and CAlCRl are heavily regulated in a cell type-specific manner depending on which of the RAmP proteins is expressed, and furthermore the RAmP proteins can also dramatically affect the surface expression levels of CAlCR and CAlCRl 145 . Thus, a comprehensive understanding of RAmP-GPCR interactions is essential for developing therapeutics that might target the various RAmP-interacting receptors 145 .
Conclusions and perspectives
The signalling and trafficking of most GPCRs involves receptor interactions with G proteins, GRKs, arrestins and other receptors. In addition to these widespread canonical GPCR associations, there are many other types of GPCR-interacting proteins that can interact with particular receptors to fine-tune receptor activity. GPCRs are important drug targets and, because it is often desirable to achieve cell type-specific drug action in order to minimize side effects, it can be clinically useful to consider the ways in which GPCRs can be differentially modulated by therapeutics depending on the cellular context. Along these lines, there has been increasing interest over the past few years in studies on 'biased agonists' that can preferentially activate G proteinmediated over arrestin-mediated GPCR signalling pathways 151, 152 . It is worth keeping in mind that agonists are likely to be differentially biased depending on the cellular context, which is determined largely by the set of GPCR-interacting proteins that regulate receptor signalling, trafficking and/or localization in a particular cell type. Thus, uncovering the full set of GPCR-interacting proteins for receptors of clinical interest could provide novel therapeutic insights by shedding light on the fundamental mechanisms controlling the fine-tuning of GPCR activity. 
